Vicki Marie Butenschoen1, Anna Kelm1, Bernhard Meyer1, Sandro M Krieg2. 1. Department of Neurosurgery, Klinikum Rechts Der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany. 2. Department of Neurosurgery, Klinikum Rechts Der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany. Sandro.Krieg@tum.de.
Abstract
BACKGROUND: Cost-effectiveness studies gain importance in the context of rising health care expenses and treatment options. Especially in the neuro-oncological context, surgical therapy may increase overall survival, but restrain the patient by postoperative disability. Quality-adjusted life years, express treatment effects and are based on health utilities. In our study, we analyze the current evidence on health economic evaluations in glioma patients. MATERIAL AND METHODS: We performed a systematic database search including Medline and Cochrane Library. Studies were critically appraised for statistical analyzes including glioma patients, health economic modeling and detailed health outcome. Study evidence was classified according to levels of evidence for therapeutic studies from the Centre for Evidence-Based Medicine (Oxford). RESULTS: 37 studies (1995-2018) were identified, 29 matched our inclusion criteria. Studies addressed surgical cost-efficiency and/or the standard treatment, postoperative chemotherapy (n = 6) and 5-ALA (n = 3). Only 16 studies used QALY as the outcome measure, most used overall survival or life years gained (LYG). Utilities were either based on one single study (Garside et al. in Health Technol Assess 11:iii-iv, ix-221) or derived from visual analogue scale (VAS). None assessed quality of life values for specific health statuses or utilities. Incremental cost-effectiveness ratios varied from 8325€ per QALY (5-ALA) to 518,342€ per LYG (tumor treating fields). CONCLUSIONS: Only one study generated utility values to conduct cost-effectiveness analysis (CEA); most studies used indirect outcomes such as LYG or based their model on previously published data. Health economic evaluations lack specific utilities, further investigations are necessary to conduct reliable CEA in the neurosurgical context.
BACKGROUND: Cost-effectiveness studies gain importance in the context of rising health care expenses and treatment options. Especially in the neuro-oncological context, surgical therapy may increase overall survival, but restrain the patient by postoperative disability. Quality-adjusted life years, express treatment effects and are based on health utilities. In our study, we analyze the current evidence on health economic evaluations in gliomapatients. MATERIAL AND METHODS: We performed a systematic database search including Medline and Cochrane Library. Studies were critically appraised for statistical analyzes including gliomapatients, health economic modeling and detailed health outcome. Study evidence was classified according to levels of evidence for therapeutic studies from the Centre for Evidence-Based Medicine (Oxford). RESULTS: 37 studies (1995-2018) were identified, 29 matched our inclusion criteria. Studies addressed surgical cost-efficiency and/or the standard treatment, postoperative chemotherapy (n = 6) and 5-ALA (n = 3). Only 16 studies used QALY as the outcome measure, most used overall survival or life years gained (LYG). Utilities were either based on one single study (Garside et al. in Health Technol Assess 11:iii-iv, ix-221) or derived from visual analogue scale (VAS). None assessed quality of life values for specific health statuses or utilities. Incremental cost-effectiveness ratios varied from 8325€ per QALY (5-ALA) to 518,342€ per LYG (tumor treating fields). CONCLUSIONS: Only one study generated utility values to conduct cost-effectiveness analysis (CEA); most studies used indirect outcomes such as LYG or based their model on previously published data. Health economic evaluations lack specific utilities, further investigations are necessary to conduct reliable CEA in the neurosurgical context.
Entities:
Keywords:
Cost-effectiveness; Glioma; Quality of life
Authors: R Garside; M Pitt; R Anderson; G Rogers; M Dyer; S Mealing; M Somerville; A Price; K Stein Journal: Health Technol Assess Date: 2007-11 Impact factor: 4.014
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Leida M Lamers; Roger Stupp; Martin J van den Bent; Maiwenn J Al; Thierry Gorlia; Jean-Blaise Wasserfallen; Nicole Mittmann; Soo Jin Seung; Ralph Crott; Carin A Uyl-de Groot Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Gabriel Rogers; Ruth Garside; Stuart Mealing; Martin Pitt; Rob Anderson; Matthew Dyer; Ken Stein; Margaret Somerville Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981